DOCSLIB.ORG

ASPA Gene Aspartoacylase

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ASPA gene aspartoacylase Normal Function The ASPA gene provides instructions for making an enzyme called aspartoacylase. In the brain, this enzyme breaks down a compound called N-acetyl-L-aspartic acid (NAA) into aspartic acid (an amino acid that is a building block of many proteins) and another molecule called acetic acid. The production and breakdown of NAA appears to be critical for maintaining the brain's white matter, which consists of nerve fibers surrounded by a myelin sheath. The myelin sheath is the covering that protects nerve fibers and promotes the efficient transmission of nerve impulses. The precise function of NAA is unclear. Researchers had suspected that it played a role in the production of the myelin sheath, but recent studies suggest that NAA does not have this function. The enzyme may instead be involved in the transport of water molecules out of nerve cells (neurons). Health Conditions Related to Genetic Changes Canavan disease More than 80 mutations in the ASPA gene are known to cause Canavan disease, which is a rare inherited disorder that affects brain development. Researchers have described two major forms of this condition: neonatal/infantile Canavan disease, which is the most common and most severe form, and mild/juvenile Canavan disease. The ASPA gene mutations that cause the neonatal/infantile form severely impair the activity of aspartoacylase, preventing the breakdown of NAA and allowing this substance to build up to high levels in the brain. The mutations that cause the mild/juvenile form have milder effects on the enzyme's activity, leading to less accumulation of NAA. An excess of NAA in the brain is associated with the signs and symptoms of Canavan disease. Studies suggest that if NAA is not broken down properly, the resulting chemical imbalance interferes with the formation of the myelin sheath as the nervous system develops. A buildup of NAA also leads to the progressive destruction of existing myelin sheaths. Nerves without this protective covering malfunction, which disrupts normal brain development. While Canavan disease occurs in people of all ethnic backgrounds, it is most common Reprinted from MedlinePlus Genetics (https://medlineplus.gov/genetics/) 1 in people of Ashkenazi (eastern and central European) Jewish heritage. Two specific ASPA gene mutations cause almost all cases of the disease in people of Ashkenazi Jewish descent. One of these mutations replaces the amino acid glutamic acid with the amino acid alanine at position 285 of the enzyme (written as Glu285Ala or E285A). This genetic change greatly reduces the amount of functional aspartoacylase. The other mutation, which is written as Tyr231Ter or Y231X, prematurely stops protein production and leads to an abnormally small, nonfunctional version of the enzyme. A different ASPA gene mutation is most common in people who are not of Ashkenazi Jewish descent. This mutation substitutes the amino acid glutamic acid for the amino acid alanine at position 305 of aspartoacylase (written as Ala305Glu or A305E). This mutation also leads to the production of a nonfunctional version of the enzyme. Other Names for This Gene • ACY2 • ACY2_HUMAN • aminoacylase 2 • aminoacylase II • ASP • N-acyl-L-aspartate amidohydrolase Additional Information & Resources Tests Listed in the Genetic Testing Registry • Tests of ASPA (https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=443[geneid]) Scientific Articles on PubMed • PubMed (https://pubmed.ncbi.nlm.nih.gov/?term=%28aspartoacylase%5BTIAB%5D %29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+3600+day s%22%5Bdp%5D) Catalog of Genes and Diseases from OMIM • ASPARTOACYLASE (https://omim.org/entry/608034) Research Resources • ClinVar (https://www.ncbi.nlm.nih.gov/clinvar?term=ASPA[gene]) • NCBI Gene (https://www.ncbi.nlm.nih.gov/gene/443) Reprinted from MedlinePlus Genetics (https://medlineplus.gov/genetics/) 2 R eferences • Baslow MH. Brain N-acetylaspartate as a molecular water pump and its role inthe etiology of Canavan disease: a mechanistic explanation. J Mol Neurosci.2003;21(3): 185-90. Review. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/14645985) • Bitto E, Bingman CA, Wesenberg GE, McCoy JG, Phillips GN Jr. Structure ofaspartoacylase, the brain enzyme impaired in Canavan disease. Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):456-61. Epub 2006 Dec 28. Citation on PubMed (https ://pubmed.ncbi.nlm.nih.gov/17194761) or Free article on PubMed Central (https://ww w.ncbi.nlm.nih.gov/pmc/articles/PMC1766406/) • Guo F, Bannerman P, Mills Ko E, Miers L, Xu J, Burns T, Li S, Freeman E, McDonough JA, Pleasure D. Ablating N-acetylaspartate prevents leukodystrophy in aCanavan disease model. Ann Neurol. 2015 May;77(5):884-8. doi: 10.1002/ana. 24392. Epub 2015 Mar 27. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/25 712859) • Hershfield JR, Pattabiraman N, Madhavarao CN, Namboodiri MA. Mutationalanalysis of aspartoacylase: implications for Canavan disease. Brain Res. 2007 May7;1148:1-14. Epub 2007 Mar 3. Citation on PubMed (https://pubmed.ncbi.n lm.nih.gov/17391648) or Free article on PubMed Central (https://www.ncbi.nlm.nih.g ov/pmc/articles/PMC1933483/) • Madhavarao CN, Arun P, Moffett JR, Szucs S, Surendran S, Matalon R, Garbern J, Hristova D, Johnson A, Jiang W, Namboodiri MA. Defective N- acetylaspartatecatabolism reduces brain acetate levels and myelin lipid synthesis in Canavan'sdisease. Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5221-6. Epub 2005 Mar 22. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/15784740) or Free article on PubMed Central (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5 55036/) • Namboodiri AM, Peethambaran A, Mathew R, Sambhu PA, Hershfield J, Moffett JR, Madhavarao CN. Canavan disease and the role of N-acetylaspartate in myelinsynthesis. Mol Cell Endocrinol. 2006 Jun 27;252(1-2):216-23. Epub 2006 May 2.Review. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/16647192) • Sommer A, Sass JO. Expression of aspartoacylase (ASPA) and Canavan disease. Gene. 2012 Sep 1;505(2):206-10. doi: 10.1016/j.gene.2012.06.036. Epub 2012 Jun28. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/22750302) • Tacke U, Olbrich H, Sass JO, Fekete A, Horvath J, Ziyeh S, Kleijer WJ, RollandMO, Fisher S, Payne S, Vargiami E, Zafeiriou DI, Omran H. Possiblegenotype-phenotype correlations in children with mild clinical course of Canavan disease. Neuropediatrics. 2005 Aug;36(4):252-5. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/16138 249) • Zano S, Wijayasinghe YS, Malik R, Smith J, Viola RE. Relationship betweenenzyme properties and disease progression in Canavan disease. J Inherit MetabDis. 2013 Jan;36(1):1-6. doi: 10.1007/s10545-012-9520-z. Epub 2012 Aug 1. Erratumin: J Inherit Metab Dis. 2013 Jan;36(1):159-60. Citation on PubMed (https://p ubmed.ncbi.nlm.nih.gov/22850825) • Zeng BJ, Pastores GM, Leone P, Raghavan S, Wang ZH, Ribeiro LA, Torres P, Reprinted from MedlinePlus Genetics (https://medlineplus.gov/genetics/) 3 Ong E, Kolodny EH. Mutation analysis of the aspartoacylase gene in non-Jewishpatients with Canavan disease. Adv Exp Med Biol. 2006;576:165-73; discussion361-3. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/16802711) • Zeng BJ, Wang ZH, Torres PA, Pastores GM, Leone P, Raghavan SS, Kolodny EH. Rapid detection of three large novel deletions of the aspartoacylase gene innon- Jewish patients with Canavan disease. Mol Genet Metab. 2006Sep-Oct;89(1-2):156- 63. Epub 2006 Jul 18. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/168546 07) Genomic Location The ASPA gene is found on chromosome 17 (https://medlineplus.gov/genetics/chromos ome/17/). Page last updated on 18 August 2020 Page last reviewed: 1 April 2015 Reprinted from MedlinePlus Genetics (https://medlineplus.gov/genetics/) 4.
Recommended publications
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
  • Global Histone Modification Fingerprinting in Human Cells Using

    Global Histone Modification Fingerprinting in Human Cells Using

    OPEN Citation: Cell Death Discovery (2017) 3, 16077; doi:10.1038/cddiscovery.2016.77 Official journal of the Cell Death Differentiation Association www.nature.com/cddiscovery ARTICLE Global histone modification fingerprinting in human cells using epigenetic reverse phase protein array Marina Partolina1,HazelCThoms1, Kenneth G MacLeod2, Giovanny Rodriguez-Blanco1,MatthewNClarke1, Anuroop V Venkatasubramani1,3, Rima Beesoo4, Vladimir Larionov5, Vidushi S Neergheen-Bhujun4, Bryan Serrels2, Hiroshi Kimura6, Neil O Carragher2 and Alexander Kagansky1,7 The balance between acetylation and deacetylation of histone proteins plays a critical role in the regulation of genomic functions. Aberrations in global levels of histone modifications are linked to carcinogenesis and are currently the focus of intense scrutiny and translational research investments to develop new therapies, which can modify complex disease pathophysiology through epigenetic control. However, despite significant progress in our understanding of the molecular mechanisms of epigenetic machinery in various genomic contexts and cell types, the links between epigenetic modifications and cellular phenotypes are far from being clear. For example, enzymes controlling histone modifications utilize key cellular metabolites associated with intra- and extracellular feedback loops, adding a further layer of complexity to this process. Meanwhile, it has become increasingly evident that new assay technologies which provide robust and precise measurement of global histone modifications are required,
  • Lineage-Specific Programming Target Genes Defines Potential for Th1 Temporal Induction Pattern of STAT4

    Lineage-Specific Programming Target Genes Defines Potential for Th1 Temporal Induction Pattern of STAT4

    Downloaded from http://www.jimmunol.org/ by guest on October 1, 2021 is online at: average * The Journal of Immunology published online 26 August 2009 from submission to initial decision 4 weeks from acceptance to publication J Immunol http://www.jimmunol.org/content/early/2009/08/26/jimmuno l.0901411 Temporal Induction Pattern of STAT4 Target Genes Defines Potential for Th1 Lineage-Specific Programming Seth R. Good, Vivian T. Thieu, Anubhav N. Mathur, Qing Yu, Gretta L. Stritesky, Norman Yeh, John T. O'Malley, Narayanan B. Perumal and Mark H. Kaplan Submit online. Every submission reviewed by practicing scientists ? is published twice each month by http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://www.jimmunol.org/content/suppl/2009/08/26/jimmunol.090141 1.DC1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* • Why • • Material Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of October 1, 2021. Published August 26, 2009, doi:10.4049/jimmunol.0901411 The Journal of Immunology Temporal Induction Pattern of STAT4 Target Genes Defines Potential for Th1 Lineage-Specific Programming1 Seth R. Good,2* Vivian T. Thieu,2† Anubhav N. Mathur,† Qing Yu,† Gretta L.
  • Generated by SRI International Pathway Tools Version 25.0, Authors S

    Generated by SRI International Pathway Tools Version 25.0, Authors S

    Authors: Pallavi Subhraveti Ron Caspi Quang Ong Peter D Karp An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Ingrid Keseler Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. Gcf_000725805Cyc: Streptomyces xanthophaeus Cellular Overview Connections between pathways are omitted for legibility.
  • Identification of Proteins Differentially Expressed in the Conventional Renal Cell Carcinoma by Proteomic Analysis

    Identification of Proteins Differentially Expressed in the Conventional Renal Cell Carcinoma by Proteomic Analysis

    J Korean Med Sci 2005; 20: 450-5 Copyright � The Korean Academy ISSN 1011-8934 of Medical Sciences Identification of Proteins Differentially Expressed in the Conventional Renal Cell Carcinoma by Proteomic Analysis Renal cell carcinoma (RCC) is one of the most malignant tumors in urology, and Jeong Seok Hwa, Hyo Jin Park*, due to its insidious onset patients frequently have advanced disease at the time of Jae Hun Jung, Sung Chul Kam, clinical presentation. Thus, early detection is crucial in management of RCC. To Hyung Chul Park, Choong Won Kim*, identify tumor specific proteins of RCC, we employed proteomic analysis. We pre- Kee Ryeon Kang*, Jea Seog Hyun, Ky Hyun Chung pared proteins from conventional RCC and the corresponding normal kidney tis- sues from seven patients with conventional RCC. The expression of proteins was Department of Urology and Biochemistry*, College of determined by silver stain after two-dimensional polyacrylamide gel electrophore- Medicine and Institute of Health Science, sis (2D-PAGE). The overall protein expression patterns in the RCC and the normal Gyeongsang National University, Jinju, Korea kidney tissues were quite similar except some areas. Of 66 differentially expressed Received : 29 December 2004 protein spots (p<0.05 by Student t-test), 8 different proteins from 11 spots were Accepted : 13 January 2005 identified by MALDI-TOF-MS. The expression of the following proteins was repress- ed (p<0.05); aminoacylase-1, enoyl-CoA hydratase, aldehyde reductase, tropo- Address for correspondence myosin -4 chain, agmatinase and ketohexokinase. Two proteins, vimentin and -1 Jeong Seok Hwa, M.D. Department of Urology, College of Medicine, antitrypsin precursor, were dominantly expressed in RCC (p<0.05).
  • Neutrophils Regulate Humoral Autoimmunity by Restricting Interferon-Γ Production Via the Generation of Reactive Oxygen Species

    Neutrophils Regulate Humoral Autoimmunity by Restricting Interferon-Γ Production Via the Generation of Reactive Oxygen Species

    UCSF UC San Francisco Previously Published Works Title Neutrophils Regulate Humoral Autoimmunity by Restricting Interferon-γ Production via the Generation of Reactive Oxygen Species Permalink https://escholarship.org/uc/item/3dn9r8j2 Journal Cell Reports, 12(7) ISSN 0022-1767 Authors Huang, X Li, J Dorta-Estremera, S et al. Publication Date 2015-08-18 DOI 10.1016/j.celrep.2015.07.021 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Article Neutrophils Regulate Humoral Autoimmunity by Restricting Interferon-g Production via the Generation of Reactive Oxygen Species Graphical Abstract Authors Xinfang Huang, Jingjing Li, Stephanie Dorta-Estremera, ..., Kimberly S. Schluns, Lewis L. Lanier, Wei Cao Correspondence [email protected] In Brief Huang et al. find that IFN-a/b produced by plasmacytoid dendritic cells (pDCs) stimulates NK cells to secrete IFN-g, which is essential for the development of autoantibodies. ROS-producing neutrophils negatively regulate this NK- IFN-g pathway and control autoimmune progression in lupus-prone mice. Highlights d Mice pre-depleted of neutrophils develop more autoantibodies after pDC activation d The pDC-IFN-a/b pathway stimulates NK cells to produce IFN-g by inducing IL-15 d ROS released by neutrophils decreases IL-15 and thus inhibits IFN-g production d Neutrophils in male NZB/W F1 mice suppress NK cell and autoimmune B cell activation Huang et al., 2015, Cell Reports 12, 1120–1132 August 18, 2015 ª2015 The Authors http://dx.doi.org/10.1016/j.celrep.2015.07.021 Cell Reports Article Neutrophils Regulate Humoral Autoimmunity by Restricting Interferon-g Production via the Generation of Reactive Oxygen Species Xinfang Huang,1,2,7 Jingjing Li,1,7 Stephanie Dorta-Estremera,1,3 Jeremy Di Domizio,1,8 Scott M.
  • CUMMINGS-DISSERTATION.Pdf (4.094Mb)

    CUMMINGS-DISSERTATION.Pdf (4.094Mb)

    D-AMINOACYLASES AND DIPEPTIDASES WITHIN THE AMIDOHYDROLASE SUPERFAMILY: RELATIONSHIP BETWEEN ENZYME STRUCTURE AND SUBSTRATE SPECIFICITY A Dissertation by JENNIFER ANN CUMMINGS Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY December 2010 Major Subject: Chemistry D-AMINOACYLASES AND DIPEPTIDASES WITHIN THE AMIDOHYDROLASE SUPERFAMILY: RELATIONSHIP BETWEEN ENZYME STRUCTURE AND SUBSTRATE SPECIFICITY A Dissertation by JENNIFER ANN CUMMINGS Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Approved by: Chair of Committee, Frank Raushel Committee Members, Paul Lindahl David Barondeau Gregory Reinhart Head of Department, David Russell December 2010 Major Subject: Chemistry iii ABSTRACT D-Aminoacylases and Dipeptidases within the Amidohydrolase Superfamily: Relationship Between Enzyme Structure and Substrate Specificity. (December 2010) Jennifer Ann Cummings, B.S., Southern Oregon University; M.S., Texas A&M University Chair of Advisory Committee: Dr. Frank Raushel Approximately one third of the genes for the completely sequenced bacterial genomes have an unknown, uncertain, or incorrect functional annotation. Approximately 11,000 putative proteins identified from the fully-sequenced microbial genomes are members of the catalytically diverse Amidohydrolase Superfamily. Members of the Amidohydrolase Superfamily separate into 24 Clusters of Orthologous Groups (cogs). Cog3653 includes proteins annotated as N-acyl-D-amino acid deacetylases (DAAs), and proteins within cog2355 are homologues to the human renal dipeptidase. The substrate profiles of three DAAs (Bb3285, Gox1177 and Sco4986) and six microbial dipeptidase (Sco3058, Gox2272, Cc2746, LmoDP, Rsp0802 and Bh2271) were examined with N-acyl-L-, N-acyl-D-, L-Xaa-L-Xaa, L-Xaa-D-Xaa and D-Xaa-L-Xaa substrate libraries.
  • WO2019226953A1.Pdf

    WO2019226953A1.Pdf

    ) ( 2 (51) International Patent Classification: Street, Brookline, MA 02446 (US). WILSON, Christo¬ C12N 9/22 (2006.01) pher, Gerard; 696 Main Street, Apartment 311, Waltham, MA 0245 1(US). DOMAN, Jordan, Leigh; 25 Avon Street, (21) International Application Number: Somverville, MA 02143 (US). PCT/US20 19/033 848 (74) Agent: HEBERT, Alan, M. et al. ;Wolf, Greenfield, Sacks, (22) International Filing Date: P.C., 600 Atlanitc Avenue, Boston, MA 02210-2206 (US). 23 May 2019 (23.05.2019) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection av ailable) . AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/675,726 23 May 2018 (23.05.2018) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/677,658 29 May 2018 (29.05.2018) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (71) Applicants: THE BROAD INSTITUTE, INC. [US/US]; MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 415 Main Street, Cambridge, MA 02142 (US). PRESI¬ OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, DENT AND FELLOWS OF HARVARD COLLEGE SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US).
  • Genetic Testing Policy Number: PG0041 ADVANTAGE | ELITE | HMO Last Review: 04/11/2021

    Genetic Testing Policy Number: PG0041 ADVANTAGE | ELITE | HMO Last Review: 04/11/2021

    Genetic Testing Policy Number: PG0041 ADVANTAGE | ELITE | HMO Last Review: 04/11/2021 INDIVIDUAL MARKETPLACE | PROMEDICA MEDICARE PLAN | PPO GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each individual policyholder terms, conditions, exclusions and limitations contract. It does not constitute a contract or guarantee regarding coverage or reimbursement/payment. Paramount applies coding edits to all medical claims through coding logic software to evaluate the accuracy and adherence to accepted national standards. This medical policy is solely for guiding medical necessity and explaining correct procedure reporting used to assist in making coverage decisions and administering benefits. SCOPE X Professional X Facility DESCRIPTION A genetic test is the analysis of human DNA, RNA, chromosomes, proteins, or certain metabolites in order to detect alterations related to a heritable or acquired disorder. This can be accomplished by directly examining the DNA or RNA that makes up a gene (direct testing), looking at markers co-inherited with a disease-causing gene (linkage testing), assaying certain metabolites (biochemical testing), or examining the chromosomes (cytogenetic testing). Clinical genetic tests are those in which specimens are examined and results reported to the provider or patient for the purpose of diagnosis, prevention or treatment in the care of individual patients. Genetic testing is performed for a variety of intended uses: Diagnostic testing (to diagnose disease) Predictive
  • Inhibition of N-Acetylglutamate Synthase by Various Monocarboxylic and Dicarboxylic Short-Chain Coenzyme a Esters and the Production of Alternative Glutamate Esters☆

    Inhibition of N-Acetylglutamate Synthase by Various Monocarboxylic and Dicarboxylic Short-Chain Coenzyme a Esters and the Production of Alternative Glutamate Esters☆

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1842 (2014) 2510–2516 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbadis Inhibition of N-acetylglutamate synthase by various monocarboxylic and dicarboxylic short-chain coenzyme A esters and the production of alternative glutamate esters☆ M. Dercksen a,b,⁎, L. IJlst a, M. Duran a, L.J. Mienie b, A. van Cruchten a, F.H. van der Westhuizen b, R.J.A. Wanders a a Laboratory Genetic Metabolic Diseases, Departments of Pediatrics and Clinical Chemistry, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands b Centre for Human Metabonomics, North-West University (Potchefstroom Campus), Hoffman street 11, Potchefstroom, South Africa, 2520 article info abstract Article history: Hyperammonemia is a frequent finding in various organic acidemias. One possible mechanism involves the Received 11 December 2012 inhibition of the enzyme N-acetylglutamate synthase (NAGS), by short-chain acyl-CoAs which accumulate due Received in revised form 9 April 2013 to defective catabolism of amino acids and/or fatty acids in the cell. The aim of this study was to investigate the Accepted 29 April 2013 effect of various acyl-CoAs on the activity of NAGS in conjunction with the formation of glutamate esters. NAGS Available online 2 May 2013 activity was measured in vitro using a sensitive enzyme assay with ultraperformance liquid chromatography– – Keywords: tandem mass spectrometry (UPLC MS/MS) product analysis. Propionyl-CoA and butyryl-CoA proved to be the N-acetylglutamate synthase most powerful inhibitors of N-acetylglutamate (NAG) formation.
  • Canavan Disease: a Neurometabolic Disease Caused by Aspartoacylase Deficiency

    Canavan Disease: a Neurometabolic Disease Caused by Aspartoacylase Deficiency

    Journal of Pediatric Sciences SPECIAL ISSUE Current opinion in pediatric metabolic disease Editor: Ertan MAYATEPEK Canavan Disease: A Neurometabolic Disease Caused By Aspartoacylase Deficiency Ute Lienhard and Jörn Oliver Sass Journal of Pediatric Sciences 2011;3(1):e71 How to cite this article: Lienhard U, Sass JO. Canavan disease: a neurometabolic disease caused by aspartoacylase deficiency. Journal of Pediatric Sciences. 2011;3(1):e71 JPS 2 REVIEW ARTICLE Canavan Disease: A Neurometabolic Disease Caused By Aspartoacylase Deficiency Ute Lienhard and Jörn Oliver Sass Abstract: Canavan disease is a genetic neurodegenerative disorder caused by mutations in the ASPA gene encoding aspartoacylase, also known as aminoacylase 2. Important clinical features comprise progressive psychomotor delay, macrocephaly, muscular hypotonia as well as spasticity and visual impairment. Cerebral imaging usually reveals leukodystrophy. While it is often expected that patients with Canavan disease will die in childhood, there is increasing evidence for heterogeneity of the clinical phenotype. Aspartoacylase catalyzes the hydrolysis of N- acetylaspartate (NAA) to aspartate and acetate. Its deficiency leads to accumulation of NAA in the brain, blood, cerebrospinal fluid and in the urine of the patients. High levels of NAA in urine are detectable via the assessment of organic acids by gas chromatography - mass spectrometry. Confirmation is available by enzyme activity tests and mutation analyses. Up to now, treatment of patients with Canavan disease is only symptomatic. Although it is a panethnic disorder, information on affected individuals in populations of other than Ashkenazi Jewish origin is rather limited. Ongoing research aims at a better understanding of Canavan disease (and of related inborn errors of metabolism such as aminoacylase 1 deficiency).
  • Aspartoacylase Is a Regulated Nuclear-Cytoplasmic Enzyme

    Aspartoacylase Is a Regulated Nuclear-Cytoplasmic Enzyme

    The FASEB Journal • FJ Express Full-Length Article Aspartoacylase is a regulated nuclear-cytoplasmic enzyme Jeremy R. Hershfield,* Chikkathur N. Madhavarao,* John R. Moffett,* Joyce A. Benjamins,† James Y. Garbern,†,‡ and Aryan Namboodiri*,1 *Department of Anatomy, Physiology, and Genetics, The Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA; †Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA; ‡Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, Michigan, USA ABSTRACT Mutations in the gene for aspartoacylase mental increases in ASPA and NAA correlate with (ASPA), which catalyzes deacetylation of N-acetyl-L- myelination (3–8) and several studies have shown aspartate in the central nervous system (CNS), result in incorporation of acetate from NAA into myelin lipids Canavan Disease, a fatal dysmyelinating disease. Con- (9–13). Overall acetate levels and lipid synthesis have sistent with its role in supplying acetate for myelin lipid recently been shown to be deficient in brains of CD synthesis, ASPA is thought to be cytoplasmic. Here we knockout mice (14), providing strong support for the describe the occurrence of ASPA within nuclei of rat hypothesis that NAA in the CNS supplies acetyl groups brain and kidney, and in cultured rodent oligodendro- for lipid synthesis during myelination (3, 7, 14). The cytes. Immunohistochemistry showed cytoplasmic and functions served by ASPA in other tissues such as kidney nuclear ASPA staining, the specificity of which was (17) are currently unknown. demonstrated by its absence from tissues of the Tremor ASPA activity was originally found to be restricted to rat, an ASPA-null mutant.